Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
Amy Peasland(Newcastle University), Nicola J. Curtin(Newcastle University), Jann N. Sarkaria(Mayo Clinic in Arizona), L-Z Wang(Newcastle University), Suzanne Kyle(Newcastle University), Richard J. Edmondson(Manchester Academic Health Science Centre), Adam P. Hopkins(Newcastle University), Gary Beale(Epistem (United Kingdom)), William A. Cliby(Mayo Clinic in Arizona), T Chen(Newcastle University), Emily J. Rowling(Newcastle University)
Cited by 193
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Overexpression of a kinase‐inactive ATR protein causes sensitivity to DNA‐damaging agents and defects in cell cycle checkpoints
|The EMBO Journal|1998|532
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
|Journal of Clinical Oncology|2008|275
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases
|British Journal of Pharmacology|2017|210